Meeting
2013 Gastrointestinal Cancers Symposium
Prospective evaluation of a 12-gene assay on treatment recommendations in patients with stage II colon cancer.
Authors
Geetika Srivastava
Mayo Clinic
Geetika Srivastava , Lindsay Renfro , Robert Behrens , Margarita Lopatin , Calvin Chao , Gamini Soori , Shaker Dakhil , Rex Mowat , J. Kuebler , George Kim , Miroslaw Mazurczak , Mark Lee , Steven Alberts
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr453)
DOI
10.1200/jco.2013.31.4_suppl.453
Abstract #
453
Poster Bd #
C9
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Patient-specific meta-analysis of 3 validation studies of the 12-gene colon cancer recurrence score assay for recurrence risk assessment after surgery with or without 5FU and oxaliplatin.
First Author: Greg Yothers
Poster
2018 Gastrointestinal Cancers Symposium
Prospective multicenter study of the impact of the 12-gene assay recurrence score on adjuvant chemotherapy treatment recommendations for stage II/III colon cancer in the post-IDEA era: SUNRISE-Decision Impact study.
First Author: Takeharu Yamanaka
Poster
2015 ASCO Annual Meeting
Time-dependent patterns of recurrence and death in resected colon cancer (CC): Pooled analysis of 12,223 patients from modern trials in the ACCENT database containing oxaliplatin.
First Author: Lindsay A. Renfro
Poster
2014 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC).
First Author: Jeanne Tie